Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Melanoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Liposarcoma 1Leiomyosarcoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Doxorubicin 3ribociclib 2Radiation Dose Hypofractionation 2nilotinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1cemiplimab 1brostallicin 1Temozolomide 1Radiotherapy 1Neoadjuvant Therapy 1Molecular Diagnostic Techniques 1Microarray Analysis 1Ifosfamide 1Docetaxel 1Diathermy 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Liposarcoma × cemiplimab × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡